Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease

O. Kim (Seoul, Republic of Korea), B. Kwon (Seoul, Republic of Korea), Y. Koh (Seoul, Republic of Korea), W. Kim (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea), Y. Oh (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), C. Lim (Seoul, Republic of Korea), C. Choi (Seoul, Republic of Korea), J. Huh (Seoul, Republic of Korea), S. Hong (Seoul, Republic of Korea), T. Shim (Seoul, Republic of Korea), K. Jo (Seoul, Republic of Korea)

Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria
Session: Challenges in treating tuberculosis and nontuberculous mycobacteria
Session type: Poster Discussion
Number: 538
Disease area: Respiratory infections

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O. Kim (Seoul, Republic of Korea), B. Kwon (Seoul, Republic of Korea), Y. Koh (Seoul, Republic of Korea), W. Kim (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea), Y. Oh (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), C. Lim (Seoul, Republic of Korea), C. Choi (Seoul, Republic of Korea), J. Huh (Seoul, Republic of Korea), S. Hong (Seoul, Republic of Korea), T. Shim (Seoul, Republic of Korea), K. Jo (Seoul, Republic of Korea). Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease. 538

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: